Abstract: An apparatus for forming glass tubes is provided. The apparatus includes a Danner-pipe, a heating device, and a heating chamber having the Danner-pipe and the heating device arranged therein. The Danner-pipe is inclined with respect to a horizontal plane by a Danner-angle. The heating device is inclined with respect to the horizontal plane by a heating-angle. The Danner-angle and/or the heating angle are in a range of 1° to 45°.

Abstract: A glass tube has a center axis, where for the glass tube a specific cross-sectional plane is defined which includes the center axis and which is parallel to the center axis. Within the specific cross-sectional plane, for each pair of outer diameters d1 and d2 of the glass tube at any two arbitrarily selected first axial position x1 and second axial positions x2 along the center axis, respectively, the following relation is 60 or smaller: |(d2?d1)/(x2?x1)|*(10{circumflex over (?)}6 mm)/d1.

Abstract: A glass tube for pharmaceutical containers and a process for the production of a glass tube are provided. The glass tubes have low alkali leachability and are devoid of a lamp ring.

Abstract: An apparatus for forming glass tubes is provided. The apparatus includes a Danner-pipe, a heating device, and a heating chamber having the Danner-pipe and the heating device arranged therein. The Danner-pipe is inclined with respect to a horizontal plane by a Danner-angle. The heating device is inclined with respect to the horizontal plane by a heating-angle. The Danner-angle and/or the heating angle are in a range of 1° to 45°.

Abstract: A glass includes a composition which is characterized by the following constituent phases of the glass: 20-80 mol % silicon dioxide; 0-40 mol % wollastonite; 0-30 mol % cordierite; 0-40 mol % anorthite; 0-40 mol % strontium-feldspar; 0-20 mol % celsian; 0-40 mol % hardystonite; 0-10 mol % titanite; and 0-15 mol % gittinsite. Where the composition is specified in mol % relative to oxides, the glass contains less than 11.5 mol % Al2O3 and less than 5000 ppm (molar, relative to the oxides) of each of B2O3, Li2O, Na2O, K2O, Rb2O and Cs2O. A calculated value for the removal rate according to ISO 695 is not more than 81.9 mg/(dm2 3 h) and a calculated value for the removal rate in acid according to DIN12116 is less than 3.5 mg(dm2 6 h).

Abstract: A container of glass and a method for chemically prestressing such a container of glass are provided. The container of glass includes a hollow body with an internal volume, a wall with an inside surface, which borders the internal volume of the hollow body, and an outside surface opposite the inside surface. The wall has, at least in a partial region, a zone with compressive stress formed bordering the outside surface, as a result of which the outside surface is compression-prestressed at least in a partial region. The inside surface of the wall opposite this partial region is free from compressive stresses and is under tensile stress.

Abstract: A method for producing glass vials, in particular pharmaceutical vials or pharmaceutical ampoules, from a glass tube is provided, the method including the following steps: (a) rotating the glass tube about a longitudinal axis thereof; (b) locally heating the glass tube from one side by means of at least one burner to at least the softening temperature of the glass; (c) reducing the diameter by pressing at least one forming body laterally against the heated region; and (d) separating the glass tube by means of a burner. A glass vial produced in such a way releases a reduced amount of alkali in accordance with ISO 4802 and has a decreased delamination tendency. Furthermore, in the hot-formed peripheral region, the alkali content is only slightly reduced when compared with the alkali content in the glass interior.

Abstract: A method for producing glass vials, in particular pharmaceutical vials or pharmaceutical ampoules, from a glass tube is provided, the method including the following steps: (a) rotating the glass tube about a longitudinal axis thereof; (b) locally heating the glass tube from one side by means of at least one burner to at least the softening temperature of the glass; (c) reducing the diameter by pressing at least one forming body laterally against the heated region; and (d) separating the glass tube by means of a burner. A glass vial produced in such a way releases a reduced amount of alkali in accordance with ISO 4802 and has a decreased delamination tendency. Furthermore, in the hot-formed peripheral region, the alkali content is only slightly reduced when compared with the alkali content in the glass interior.

Abstract: A pharmaceutical packaging is provided including a glass, comprising at least the following components (given in mol % on oxide basis): SiO2: 5 9-84, Al2O3: 7-18.5, CaO: 1-25, SrO: 0-6.5, BaO: 0-5, ZrO2: 0-3, TiO2: 0-5, B2O3: 0-1, wherein the ratio (CaO+SrO+BaO)/Al2O3<2.8, wherein the ratio (CaO+SrO+BaO)/SiO2?0.39, wherein the hydrolytic resistance according to DIN ISO 720 is class HGA 1, and wherein the glass, apart from unavoidable contaminations, is free of alkali oxides and magnesium oxides.

Abstract: A zirconium-free neutral glass is provided that finds use in the pharmaceutical sector. The glass has a combination of alkali metal oxides of sodium, potassium and optionally lithium, and a controlled amount of aluminum oxide, which provides a zirconium-free and low-boron neutral glass having good hydrolytic stability, good acid and alkali stability and good devitrification properties. The glass includes the following components in % by weight: SiO2 ?72-82, B2O3 ??3-8, Al2O3 ??5-8, Na2O 2.5-5.5, K2O 3.6-8.4, Li2O ??0-0.7, MgO ??0-0.7, CaO ??0-0.4, and TiO2 ??0-5, wherein Li2O + Na2O + K2O 6.8-14.6, and K2O/Na2O ratio 0.7-3.4.

Abstract: A pharmaceutical packaging is provided including a glass, comprising at least the following components (given in mol % on oxide basis): SiO2:59-84, Al2O3:7-18.5, CaO:1-25, SrO:0-6.5, BaO:0-5, ZrO2:0-3, TiO2:0-5, B2O3:0-1, wherein the ratio (CaO+SrO+BaO)/Al2O3<2.8, wherein the ratio (CaO+SrO+BaO)/SiO2?0.39, wherein the hydrolytic resistance according to DIN ISO 720 is class HGA 1, and wherein the glass, apart from unavoidable contaminations, is free of alkali oxides and magnesium oxides.

Abstract: Borosilicate glasses, preferably for use in the pharmaceutical sector, are provided. The borosilicate glasses are outstandingly suitable for the use as pharmaceutical primary packaging, such as phials or ampoules, since the aqueous or water-containing medicaments kept in the containers do not attack the glass significantly, and so the glass releases no, or only few, ions. The borosilicate glasses have the following composition in % by weight or consist thereof: SiO2 71-77; B2O3 9-12; Al2O3 5.5-8; Na2O 6-8; K2O 0.1-0.9; Li2O 0-0.3; CaO 0-1.5; BaO 0-1; F 0-0.3; Cl- 0-0.3; and MgO + CaO + BaO + SrO 0-2.

Abstract: A zirconium-free neutral glass is provided that finds use in the pharmaceutical sector. The glass has a combination of alkali metal oxides of sodium, potassium and optionally lithium, and a controlled amount of aluminium oxide, which provides a zirconium-free and low-boron neutral glass having good hydrolytic stability, good acid and alkali stability and good devitrification properties. The glass includes the following components in % by weight: SiO2 ?72-82, B2O3 ??3-8, Al2O3 ??5-8, Na2O 2.5-5.5, K2O 3.6-8.4, Li2O ??0-0.7, MgO ??0-0.7, CaO ??0-0.4, and TiO2 ??0-5, wherein Li2O + Na2O + K2O 6.8-14.6, and K2O/Na2O ratio 0.7-3.4.

Abstract: A method for producing glass vials, in particular pharmaceutical vials or pharmaceutical ampoules, from a glass tube is provided, the method including the following steps: (a) rotating the glass tube about a longitudinal axis thereof; (b) locally heating the glass tube from one side by means of at least one burner to at least the softening temperature of the glass; (c) reducing the diameter by pressing at least one forming body laterally against the heated region; and (d) separating the glass tube by means of a burner. A glass vial produced in such a way releases a reduced amount of alkali in accordance with ISO 4802 and has a decreased delamination tendency. Furthermore, in the hot-formed peripheral region, the alkali content is only slightly reduced when compared with the alkali content in the glass interior.

Abstract: Borosilicate glasses, preferably for use in the pharmaceutical sector, are provided. The borosilicate glasses are outstandingly suitable for the use as pharmaceutical primary packaging, such as phials or ampoules, since the aqueous or water-containing medicaments kept in the containers do not attack the glass significantly, and so the glass releases no, or only few, ions. The borosilicate glasses have the following composition in % by weight or consist thereof: SiO2 71-77; B2O3 9-12; Al2O3 5.5-8; Na2O 6-8; K2O 0.1-0.9; Li2O 0-0.3; CaO 0-1.5; BaO 0-1; F 0-0.3; Cl- 0-0.3; and MgO + CaO + BaO + SrO 0-2.

Abstract: The glass-metal bond for a tube collector includes a glass tube and metal part bonded to the glass tube. In order to match the thermal expansion properties, the glass tube has the following composition: SiO2, 73-77 wt. %; B2O3, 6-<8 wt. %; Al2O3, 6-6.5 wt. %; Na2O, 5.5-7 wt. %; K2O, 1-3 wt. %; CaO, 0.5-3.2 wt. %; MgO, 0-2 wt. %; Fe2O3, 50-150 ppm; and TiO2 0-<100 ppm. The ratio of the sum of the alkaline-earth metal oxides (in mol %) to the sum of the alkali metal oxides (in mol %) is ?0.6. The metal part is preferably made of metal material no. 1.3981 according to DIN 17745. The glass composition itself is also part of the invention.

Abstract: A process for producing a wipe-proof anti-reflection layer on a borosilicate glass body is described, in which the borosilicate glass body is coated with a coating solution having a composition of 1-6% by weight of HCl, 0.5-7% by weight of SiO2 sol (solids content), 0.5-5% by weight of H2O, and 85-98% by weight of a readily volatile water-soluble organic solvent. The borosilicate glass body that is to be coated contains, in % by weight based on oxide content: 63-76 of SiO2, >11-20 of B2O3, 1-9 of Al2O3, 3-12 of alkali metal oxide(s), 0-10 of alkaline earth metal oxide(s), 0-2 of ZnO, 0-5 of TiO2, 0-1 of ZrO2, 0-1 of Nb2O5, and 0-1 of WO3.

Abstract: In the method of making an adherent and wipe-resistant porous SiO2-containing antireflection coating on a borosilicate glass body a coating solution containing from 1.0 to 6.0 wt. % of HCl, from 0.5 to 7.0 wt. % of a SiO2 sol based on solids content, from 0.5 to 5.0 wt. % of water, and from 85 to 98 wt. % of at least one volatile water-soluble organic solvent, is used to form an antireflection coating on the glass body. A glass body, on which the foregoing coating can be provided with good adherence and wipe resistance properties, is made of borosilicate glass having a composition, in percent by weight based on oxide content, of SiO2, 70 to 75; B2O3, 8 to 11; Al2O3, 5 to 9; alkali metal oxides, 7 to 12; and alkaline earth metal oxides, 0 to 10.

Abstract: The invention discloses a method for the production of packaging made from borosilicate glass for pharmaceutical products and medical products comprising the steps of: providing a glass tube made from a borosilicate base glass, generating a temporary interface layer on an inner surface of the glass tube, hot-forming the glass tube at a temperature above Tg, and cooling down the glass tube to room temperature.

Abstract: The glass-metal bond for a tube collector includes a glass tube and metal part bonded to the glass tube. In order to match the thermal expansion properties, the glass tube has the following composition: SiO2, 73-77 wt. %; B2O3, 6-<8 wt. %; Al2O3, 6-6.5 wt. %; Na2O, 5.5-7 wt. %; K2O, 1-3 wt. %; CaO, 0.5-3.2 wt. %; MgO, 0-2 wt. %; Fe2O3, 50-150 ppm; and TiO2 0-<100 ppm. The ratio of the sum of the alkaline-earth metal oxides (in mol %) to the sum of the alkali metal oxides (in mol %) is ?0.6. The metal part is preferably made of metal material no. 1.3981 according to DIN 17745. The glass composition itself is also part of the invention.